Oxonica has raised approximately £7.1m (net of expenses) through a placing of 8,658,796 new ordinary shares at 95.8 pence per share. In addition, Oxonica shareholders have converted loans of approximately £2m into ordinary shares at 95.8 pence per share, which together with the placing strengthens the balance sheet by £9.1m.
GP and Katalist's founders are planning bolt-ons for the food and pharma supply chain software firm
Italian sports technology provider first sale attempt was hampered by the onset of COVID-19 in early 2020
Nick Chronias will lead the firm’s focus on private credit and private infrastructure secondaries
Dörte Höppner joined the GP in 2017 and will be responsible for its ESG initiatives globally